DeepMed Research

INSTITUT CURIE

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Established: 1909-01-01

Employees: 1K

Market Cap: -

Website: http://www.curie.fr

Clinical Trials

FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France

Conditions: Breast Cancer Female

Interventions: Other: questionnaires

First Posted Date: 2019-03-21

Last Posted Date: 2019-03-27

Lead Sponsor: Institut Curie

Target Recruit Count: 1004

Registration Number: NCT03884413

Locations: 🇫🇷
Seintinelles.Com, Paris, France

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Not Applicable

Recruiting

Conditions: HPV Positive Pelvic Cancer

Interventions: Procedure: Blood sampling

First Posted Date: 2018-11-14

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 172

Registration Number: NCT03739775

Locations: 🇫🇷
Hôpital Tenon, Paris, France
🇫🇷
CHU Pontchaillou, Rennes, France
🇫🇷
Institut Curie - Paris, Paris, France

and more 2 locations

Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer

Not Applicable

Completed

Conditions: Surgery
Breast Cancer

Interventions: Diagnostic Test: Sorbstar®
Diagnostic Test: Odour sampling

First Posted Date: 2018-10-12

Last Posted Date: 2020-12-22

Lead Sponsor: Institut Curie

Target Recruit Count: 15

Registration Number: NCT03703557

Locations: 🇫🇷
INSTITUT CURIE - Site de Saint Cloud, Saint-Cloud, France

Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor

Completed

Conditions: Borderline Ovarian Tumors

First Posted Date: 2018-10-01

Last Posted Date: 2019-10-30

Lead Sponsor: Institut Curie

Target Recruit Count: 176

Registration Number: NCT03690440

Locations: 🇫🇷
Centre Jean PERRIN, Clermont-Ferrand, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 8 locations

Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)

Not Applicable

Active, not recruiting

Conditions: Ewing Sarcoma Family of Tumors
Rhabdomyosarcoma
Central Nervous System Tumor
Leukemia
Neuroblastoma
Osteosarcoma

Interventions: Other: Sampling on blood, bone marrow and cerebrospinal fluid

First Posted Date: 2018-04-12

Last Posted Date: 2025-03-18

Lead Sponsor: Institut Curie

Target Recruit Count: 600

Registration Number: NCT03496402

Locations: 🇫🇷
Hôpital d'Enfants Armand-Trousseau, Paris, France
🇫🇷
Hôpital universitaire Robert-Debré (AP-HP), Paris, France
🇫🇷
Hôpital l'Archet 2, Nice, France

and more 27 locations

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months

Phase 1

Completed

Conditions: Locally Advanced Cervical Cancer
Cervical Cancer

Interventions: Drug: Nivolumab Injection
Drug: Cisplatin
Radiation: radiotherapy

First Posted Date: 2017-10-02

Last Posted Date: 2024-02-02

Lead Sponsor: Institut Curie

Target Recruit Count: 21

Registration Number: NCT03298893

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut Curie Hopital René Huguenin, Saint Cloud, France
🇫🇷
Hopital Européen Georges Pompidou, Paris, France

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)

Phase 1

Completed

Conditions: Breast Neoplasms, Triple-Negative
Breast Neoplasm Malignant Female
Radiotherapy Side Effect

Interventions: Drug: Olaparib
Radiation: Radiation therapy

First Posted Date: 2017-04-12

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 24

Registration Number: NCT03109080

Locations: 🇫🇷
Institut Curie, Paris, France

SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)

Not Applicable

Active, not recruiting

Conditions: Cancer
Solid Tumor, Adult

Interventions: Diagnostic Test: research of druggable molecular alterations on tumor biopsy

First Posted Date: 2017-03-21

Last Posted Date: 2024-02-16

Lead Sponsor: Institut Curie

Target Recruit Count: 170

Registration Number: NCT03084757

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre LEON BERARD, Lyon, France
🇫🇷
Institut Curie, Paris, France

and more 1 locations

MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)

Not Applicable

Active, not recruiting

Conditions: Hereditary Retinoblastoma

Interventions: Procedure: MRI

First Posted Date: 2017-01-20

Last Posted Date: 2024-04-30

Lead Sponsor: Institut Curie

Target Recruit Count: 88

Registration Number: NCT03026998

Locations: 🇫🇷
Institut Curie, Paris, France

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Not Applicable

Recruiting

Conditions: Ovarian Cancer
Triple-Negative Breast Cancer
Head and Neck Cancer
Cervical Cancer
Sarcoma

Interventions: Procedure: Tumor biopsies / Tumor surgery
Procedure: Blood withdrawal

First Posted Date: 2017-01-11

Last Posted Date: 2025-04-02

Lead Sponsor: Institut Curie

Target Recruit Count: 1050

Registration Number: NCT03017573

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Institut Curie Hopital Rene Huguenin, Saint-cloud, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy